Monopar Therapeutics Inc (MNPR) — Defensive Interval Ratio

Latest as of December 2025: 10 days

Monopar Therapeutics Inc (MNPR) has a Defensive Interval Ratio of 10 days as of December 2025. Defensive assets of $78.57 Million (cash $-, short-term investments $78.57 Million, receivables $-) cover 10 days of daily cash needs of $7.49 Million/day. Check MNPR intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Defensive Interval Ratio

10 days
Days of operational coverage

Defensive Assets

$78.57 Million
Cash + ST Investments + Receivables

Daily Cash Need

$7.49 Million
Current Liabilities ÷ 365

Current Liabilities

$2.74 Billion
USD

Monopar Therapeutics Inc Defensive Interval Ratio (2021–2025)

This chart shows how Monopar Therapeutics Inc's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 10 days, meaning defensive assets of $78.57 Million can fund 10 days of operations without new revenue. Also explore MNPR year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for Monopar Therapeutics Inc (2021–2025)

The table below presents the year-by-year Defensive Interval Ratio for Monopar Therapeutics Inc from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see how much is Monopar Therapeutics Inc worth.

Year DIR (days) Defensive Assets (USD) Daily Cash Need Cash ST Investments Change (days)
2025 10 days $78.57 Million $7.49 Million/day $- $78.57 Million ▼ -990 days
2024 1000 days $14.40 Million $14.40K/day $- $14.40 Million ▲ +1000 days
2023 0 days $0.00 $4.81K/day $- $0.00 ▼ -576 days
2022 576 days $4.93 Million $8.57K/day $- $4.93 Million ▲ +576 days
2021 0 days $0.00 $4.33K/day $- $0.00
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)